公开(公告)号：US20210347872A1

公开(公告)日：2021-11-11

申请号：US17285861

申请日：2019-10-15

Applicant: NEURACLE SCIENCE CO., LTD.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P27/02

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

公开(公告)号：US20210070849A1

公开(公告)日：2021-03-11

申请号：US17050056

申请日：2019-04-24

Applicant: Neuracle Science Co., Ltd.

Inventor： Bongcheol KIM ,  Dong Sik KIM ,  Soon-gu KWON

IPC: C07K16/24 ,  A61P25/02

Abstract: The present disclosure provides a method for the treatment of a neuropathic pain including a central neuropathic pain or a peripheral neuropathic pain in a subject comprising the administration of antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. The present disclosure also provides methods for treating a neuropathic pain including a symptom of neuropathic pain, and/or an underlining cause of a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5. In a specific aspect, the method comprises administering antibodies specifically bind to human FAM19A5, e.g., binds to soluble human FAM19A5 with a KD of 10 nM or less, or binds to membrane bound human FAM19A5 with a KD of 10 nM or less, or both, as measured by a method known in the art, e.g., ELISA.

公开(公告)号：US20200223914A1

公开(公告)日：2020-07-16

申请号：US16626625

申请日：2018-06-27

Applicant: Neuracle Science Co., Ltd. ,  KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

Inventor： Bongcheol KIM ,  Eun Bee CHO ,  Dong Sik KIM ,  Jae-Keun LEE ,  Soon-gu KWON ,  Jae Young SEONG ,  Juwon SHIM ,  Tae Woo KIM ,  Shin-hyuk KANG

IPC: C07K16/24 ,  A61P35/00 ,  C07K16/30

Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.